Arvinas Inc. News and Resources
CDMO News

Arvinas Licenses Prostate Cancer Drug ARV-766 to Novartis

Arvinas Inc., a clinical-stage biotechnology company, has entered an exclusive strategic license agreement with Novartis for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. The transaction also includes

Read More »
15 April 2024

Welcome to PharmaSource

Join the global community of outsourcing & procurement professionals from the world’s leading pharma and biotechs:
tick Stay ahead of trends and best practices
tick Exclusive downloads and podcasts
tick Get invites to special events and meetups
Sign up for your free membership arrow

© Life Science Networks 2024

Follow us

Top Links

Get in touch

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .
Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.

Recommend a Supplier